# Jianxing He

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jianxing-he/

## Facts

| Field | Value |
| --- | --- |
| Citations | 73,221 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 77 |
| i10-index | 472 |
| Last Known Institution | First Affiliated Hospital of Guangzhou Medical University |
| OpenAlex ID | https://openalex.org/A5100751322 |
| ORCID iD | https://orcid.org/0000-0003-1737-8192 |
| Works | 1,111 |

## Researcher papers

Showing 12 of 13.

- [Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China](https://scholariq.org/papers/cancer-patients-in-sars-cov-2-infection-a-nationwide-analysis-in-china/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19](https://scholariq.org/papers/development-and-validation-of-a-clinical-risk-score-to-predict-the-occurrence-of/)
- [Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography](https://scholariq.org/papers/clinically-applicable-ai-system-for-accurate-diagnosis-quantitative-measurements/)
- [Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis](https://scholariq.org/papers/comorbidity-and-its-impact-on-1-590-patients-with-covid-19-in-china-a-nationwide/)
- [Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-anlotinib-as-a-third-line-or-further-treatment-on-overall-survival-of/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-of-the-mage-a3-cancer-immunotherapeutic-as-adjuvant-therapy-in-patients/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry](https://scholariq.org/papers/impact-of-examined-lymph-node-count-on-precise-staging-and-long-term-survival-of/)
- [A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies](https://scholariq.org/papers/a-practical-molecular-assay-to-predict-survival-in-resected-non-squamous-non/)
- [Early triage of critically ill COVID-19 patients using deep learning](https://scholariq.org/papers/early-triage-of-critically-ill-covid-19-patients-using-deep-learning/)

## Researcher topics

- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Tracheal and airway disorders](https://scholariq.org/topics/tracheal-and-airway-disorders-2/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [First Affiliated Hospital of Guangzhou Medical University](https://scholariq.org/institutions/first-affiliated-hospital-of-guangzhou-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.